What is it about?
Pegfilgrastim (Peg-G) is a Pegylated formulation of filgrastim with a long half-life. The white blood cell count may temporarily increase after administration; in particular, a leukocyte overshoot may be observed. The present study retrospectively examined the incidence and timing of leukocyte overshoot after Peg-G administration.
Featured Image
Why is it important?
There was a higher frequency of occurrence of leukocyte overshoot in response to Peg-G, than in response to normal G-CSF. High incidence of leukocyte overshoot was observed when blood was collected 1–2 days after administration of Peg-G. It is important for patients to understand the characteristics of Peg-G by conducting pharmaceutical guidance.
Perspectives
Patients who experience leukocyte overshoot, which they have never seen before, may experience anxiety. G-CSF is a medication that increases WBC when the WBC level of a patient is low. It is important for patients to understand the characteristics of Peg-G by conducting pharmaceutical guidance. In that way, we can provide safety and relief to patients with intensive chemotherapy.
eiseki usami
ogaki municipal hospital
Read the Original
This page is a summary of: The incidence and timing of leukocyte overshoot after pegfilgrastim administration, Journal of Oncology Pharmacy Practice, April 2018, SAGE Publications,
DOI: 10.1177/1078155218769140.
You can read the full text:
Contributors
The following have contributed to this page
